William Blair analyst Andy Hsieh has reiterated their bullish stance on CRBP stock, giving a Buy rating on October 29.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andy Hsieh has given his Buy rating due to a combination of factors including Corbus Pharmaceuticals’ strong financial position and promising developments in their clinical pipeline. The company has extended its cash runway into 2028, supported by a substantial cash reserve of approximately $177.8 million, which provides a solid foundation for ongoing and future research initiatives.
Additionally, the promising data of CRB-701 in head and neck cancer presented at ESMO has set the stage for a pivotal trial initiation in mid-2026, reflecting potential future growth. The planned initiation of a Phase Ib study for CRB-913 in obesity and the upcoming announcement of Phase I data for CRB-601 further highlight the company’s active engagement in advancing its pipeline, which could lead to significant clinical and commercial success.
In another report released on October 29, Mizuho Securities also maintained a Buy rating on the stock with a $39.00 price target.